What is Zacks Research's Forecast for IRWD Q3 Earnings?

Key Points

• Analysts at Zacks Research have lowered their Q3 2026 earnings per share estimate for Ironwood Pharmaceuticals to $0.12, down from $0.13, maintaining a "Hold" rating on the stock.
• In contrast, Wall Street Zen upgraded Ironwood Pharmaceuticals from a "hold" to a "strong-buy" rating, while the consensus price target remains at $4.94.
• Several large investors have significantly increased their positions in Ironwood Pharmaceuticals, with Marshall Wace LLP notably raising its ownership by 616.3% in the second quarter.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Equities research analysts at Zacks Research cut their Q3 2026 EPS estimates for Ironwood Pharmaceuticals in a report released on Monday, September 8th. Zacks Research analyst Team now anticipates that the biotechnology company will earn $0.12 per share for the quarter, down from their prior estimate of $0.13. Zacks Research has a "Hold" rating on the stock. The consensus estimate for Ironwood Pharmaceuticals' current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals' Q1 2027 earnings at ($0.02) EPS.

Separately, Wall Street Zen raised shares of Ironwood Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 9th. One investment analyst has rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average target price of $4.94.

Ironwood Pharmaceuticals Price Performance

Shares of IRWD stock traded down $0.02 on Wednesday, reaching $1.30. 366,481 shares of the company were exchanged, compared to its average volume of 2,699,081. The company has a market cap of $210.35 million, a price-to-earnings ratio of -25.89 and a beta of 0.32. The company has a 50-day moving average of $0.98 and a 200-day moving average of $0.96. Ironwood Pharmaceuticals has a one year low of $0.53 and a one year high of $5.13.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biotechnology company reported $0.14 EPS for the quarter, beating analysts' consensus estimates of ($0.02) by $0.16. The business had revenue of $85.24 million for the quarter, compared to analysts' expectations of $62.02 million. Ironwood Pharmaceuticals had a negative net margin of 2.25% and a negative return on equity of 2.46%. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in IRWD. Raymond James Financial Inc. acquired a new stake in shares of Ironwood Pharmaceuticals in the 4th quarter worth about $68,000. Dimensional Fund Advisors LP increased its stake in Ironwood Pharmaceuticals by 4.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 218,422 shares of the biotechnology company's stock valued at $968,000 after buying an additional 10,149 shares during the last quarter. Hsbc Holdings PLC increased its stake in Ironwood Pharmaceuticals by 88.9% in the 4th quarter. Hsbc Holdings PLC now owns 20,886 shares of the biotechnology company's stock valued at $91,000 after buying an additional 9,828 shares during the last quarter. Northern Trust Corp increased its stake in Ironwood Pharmaceuticals by 7.9% in the 4th quarter. Northern Trust Corp now owns 1,625,110 shares of the biotechnology company's stock valued at $7,199,000 after buying an additional 118,962 shares during the last quarter. Finally, Jane Street Group LLC increased its stake in Ironwood Pharmaceuticals by 29.0% in the 4th quarter. Jane Street Group LLC now owns 417,642 shares of the biotechnology company's stock valued at $1,850,000 after buying an additional 94,004 shares during the last quarter.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.